Showing results (31-40 of 94) with videos related to
Sort By:
Pageof 10
Prostate Cancer|October 10, 2022
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate CancerRahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, et al.The Prostate|May 1, 2025
Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway InhibitorsIbrahim M Asiri, Ronald C Chen, Viraj Master, et al.Journal of Oncology Practice|December 23, 2017
Alternative Outpatient Chemotherapy Scheduling Method to Improve Patient Service Quality and Nurse SatisfactionYu-Li Huang, Alan H Bryce, Tracy Culbertson, et al.Cancers|March 29, 2023
Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning ApproachSuryadipto Sarkar, Kong Min, Waleed Ikram, et al.Journal of Gastrointestinal Oncology|January 4, 2019
Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experienceThomas T DeLeon, Marcela A Salomao, Bashar A Aqel, et al.Clinical Genitourinary Cancer|May 27, 2017
Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate CancerWilliam W Wong, Eric M Anderson, Homan Mohammadi, et al.Clinical Genitourinary Cancer|May 16, 2023
Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional StudyCorbin J Eule, Junxiao Hu, Sulaiman Al-Saad, et al.Scientific Reports|March 7, 2019
Shared and unique genomic structural variants of different histological components within testicular germ cell tumours identified with mate pair sequencingAlan H Bryce, Jan B Egan, James B Smadbeck, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2025
Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate CancerNicolas Sayegh, Ryon P Graf, Umang Swami, et al.Pharmacoepidemiology and Drug Safety|June 20, 2026
Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway InhibitorsIbrahim M Asiri, Ronald C Chen, Viraj Master, et al.Pageof 10